Indian Immunologicals wins DCGI okay to manufacture Measles-Rubella vaccine

A press release from IIL said, "IIL's Indo-Vietnam Partnership resulted in manufacturing and marketing authorisation of their Measles-Rubella (MR) Vaccine. IIL partnered with Center for Research and Production of Vaccines and Biologicals, also called Polyvac, Vietnam".

Under an exclusive agreement, Polyvac, Vietnam will supply the Measles vaccine component to IIL. Rubella Vaccine component will be produced by IIL to manufacture a combined MR vaccine, it said.

This Live Attenuated MR vaccine adds to the list of several other vaccines that IIL supplies to Universal Immunization Programme (UIP) of India, the release said.

This vaccine has been proven through extensive human clinical trials to be immunogenic and safe for people of 9 months to 49 years, it said.

Measles is a highly contagious, serious disease caused by a virus. Measles is caused by a virus in the paramyxovirus family and it is normally passed through direct contact and through the air. The virus infects the respiratory tract, then spreads throughout the body.

Rubella is an acute, contagious viral infection. The rubella virus is transmitted by airborne droplets when infected people sneeze or cough. Humans are the only known host.

K Anand Kumar, Managing Director, Indian Immunologicals Limited said, "We have successfully completed all phases of product development to the satisfaction of the regulatory authorities in India. Measles-Rubella (MR) vaccine is listed in the UIP of India and is an important vaccine for our country."